A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension

Sponsor
Joseph Kowalski (Other)
Overall Status
Completed
CT.gov ID
NCT02888093
Collaborator
International Urogynecological Association (IUGA) (Other)
44
1
2
25
1.8

Study Details

Study Description

Brief Summary

Uterosacral ligament suspension (USLS) is a commonly performed, vaginal surgery for the correction of female pelvic organ prolapse. The original description of this procedure included the use of permanent sutures. However, permanent suture use in this vaginal application can result in some minor complication such as persistent vaginal spotting, vaginal discharge and dyspareunia. Subsequent reports on this procedure have utilized delayed-absorbable sutures in order to avoid these complications. Retrospective studies are conflicting as to whether or not absorbable suture provides as durable an anatomic outcome as permanent suture. There are currently no high-quality, prospective studies that have evaluated outcomes of permanent and absorbable suture for uterosacral ligament suspension.

This study will recruit women scheduled to undergo USLS with or without other prolapse or anti-incontinence procedures. Participants will be randomized 1:1 to permanent or absorbable suture. Follow up will occur at 6 weeks and 12 months post-operatively. The primary outcome will be Pelvic Organ Prolapse Quantification Exam (POP-Q) point C as measured at the 12 month follow up visit. Subjects and assessors will be blinded.

Condition or Disease Intervention/Treatment Phase
  • Device: Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)
N/A

Detailed Description

Patient demographics, relevant histories, baseline physical exam including POP-Q and PFDI-20 data will be abstracted from the electronic medical record following enrollment. This information will be placed into a secure database.

The randomization sequence will be generated by randomize.net, a web-based service that provides comprehensive randomization services for randomized controlled trials. The sequence will be randomized 1:1 with blocks of 4 and stratified by surgeon. Concealment will be completely opaque as group allocation will not be revealed until the subject is enrolled on the web-based service and the surgeon has elected to randomize the patient from an internet connection in the operating room.

Subjects and assessors will be blinded to study group. The surgeons will, necessarily, not be blinded. Subjects will only be informed of their assigned group upon request following completion of the entire study.

USLS with the assigned suture and any scheduled concomitant prolapse and anti-incontinence procedures will be performed. All procedures will be performed by one of two fellowship-trained, Female Pelvic Medicine and Reconstructive Surgery board-certified surgeons. USLS will be performed as initially described by Shull et al with two important differences in technique. First, 2 sutures will be placed through the intermediate portion of each uterosacral ligament instead of 3. Second, when absorbable suture (polydioxanone) is used, the suture will be placed through the full thickness of the anterior and posterior vaginal walls.

Follow up exams will occur at 6 weeks and 12 months post-operatively and will include a POP-Q exam. The 6 week follow up visit will include the Patient Global Impression of Improvement (PGI-I) and an additional survey. The 12 month follow up visit will include a the PGI-I, PFDI-20 and an additional survey. All participants will also be assessed for any suture-related complications, such as erosion or granulation tissue. Follow up exams will be completed by one of two urogynecology nurse practitioners who will be blinded to the surgery and suture choice. Both nurse practitioners have extensive experience in performing POP-Q exams. The examiners will complete a follow up data abstraction form for each follow up appointment (6 weeks and 12 months).

The follow up clinic appointments at 6 weeks and 12 months are the times of usually scheduled post-operative follow up for USLS procedures. Additionally, completion of the PFDI-20 questionnaire and a POP-Q exam constitute routine clinical care for these patients. As such, there is no additional time commitment for subjects compared to routine clinical care.

Study Design

Study Type:
Interventional
Actual Enrollment :
44 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension
Actual Study Start Date :
Oct 1, 2016
Actual Primary Completion Date :
Nov 1, 2017
Actual Study Completion Date :
Nov 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Absorbable

Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)

Device: Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)

Experimental: Permanent

Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)

Device: Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)

Outcome Measures

Primary Outcome Measures

  1. Pelvic Organ Prolapse Quantification Exam (POP-Q) Point C [12 months]

    Non-inferiority of POP-Q point C. This measure was obtained as originally described by Bump et al. The hymen is used as a fixed reference point. In other words, this is point zero. Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.

Secondary Outcome Measures

  1. Suture-related Complications [6 weeks and 12 months]

    The presence of apical granulation tissue, apical suture exposure, abnormal vaginal discharge, vaginal spotting, post-coital spotting, dyspareunia or patient being able to feel suture.

  2. Symptomatic Prolapse Outcomes [12 months]

    Positive response to PFDI-20 question #3 regarding the presence of a vaginal bulge (yes) AND the presence of bother (somewhat, moderately or quite a bit).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Scheduled for uterosacral ligament suspension (USLS)
Exclusion Criteria:
  • Non-English speaking

  • Prisoner

  • Cognitive impairment precluding informed consent

  • Planned hysteropexy

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Iowa Hospitals and Clinics Iowa City Iowa United States 52245

Sponsors and Collaborators

  • Joseph Kowalski
  • International Urogynecological Association (IUGA)

Investigators

  • Principal Investigator: Joseph T Kowalski, MD, University of Iowa

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Joseph Kowalski, Female Pelvic Medicine and Reconstructive Surgery, Fellow, University of Iowa
ClinicalTrials.gov Identifier:
NCT02888093
Other Study ID Numbers:
  • 201607769
First Posted:
Sep 2, 2016
Last Update Posted:
Dec 2, 2019
Last Verified:
Nov 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

Participant Flow

Recruitment Details
Pre-assignment Detail
Arm/Group Title Absorbable Permanent
Arm/Group Description Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS) Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2) Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS) Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)
Period Title: Overall Study
STARTED 22 22
COMPLETED 20 20
NOT COMPLETED 2 2

Baseline Characteristics

Arm/Group Title Absorbable Permanent Total
Arm/Group Description Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS) Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2) Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS) Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2) Total of all reporting groups
Overall Participants 22 22 44
Age (Count of Participants)
<=18 years
0
0%
0
0%
0
0%
Between 18 and 65 years
13
59.1%
11
50%
24
54.5%
>=65 years
9
40.9%
11
50%
20
45.5%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]
62.1
(13.7)
63.6
(10.2)
62.9
(12.0)
Sex: Female, Male (Count of Participants)
Female
22
100%
22
100%
44
100%
Male
0
0%
0
0%
0
0%
Race and Ethnicity Not Collected (Count of Participants)
Count of Participants [Participants]
0
0%
Region of Enrollment (participants) [Number]
United States
22
100%
22
100%
44
100%

Outcome Measures

1. Primary Outcome
Title Pelvic Organ Prolapse Quantification Exam (POP-Q) Point C
Description Non-inferiority of POP-Q point C. This measure was obtained as originally described by Bump et al. The hymen is used as a fixed reference point. In other words, this is point zero. Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.
Time Frame 12 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Absorbable Permanent
Arm/Group Description Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS) Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2) Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS) Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)
Measure Participants 20 20
Median (Full Range) [cm]
-7.25
-7
2. Secondary Outcome
Title Suture-related Complications
Description The presence of apical granulation tissue, apical suture exposure, abnormal vaginal discharge, vaginal spotting, post-coital spotting, dyspareunia or patient being able to feel suture.
Time Frame 6 weeks and 12 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Absorbable Permanent
Arm/Group Description Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS) Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
Measure Participants 20 20
6 weeks
17
77.3%
14
63.6%
12 months
2
9.1%
4
18.2%
3. Secondary Outcome
Title Symptomatic Prolapse Outcomes
Description Positive response to PFDI-20 question #3 regarding the presence of a vaginal bulge (yes) AND the presence of bother (somewhat, moderately or quite a bit).
Time Frame 12 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Absorbable Permanent
Arm/Group Description Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS) Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
Measure Participants 20 20
Count of Participants [Participants]
1
4.5%
4
18.2%

Adverse Events

Time Frame 1 year
Adverse Event Reporting Description
Arm/Group Title Absorbable Permanent
Arm/Group Description Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS) Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2) Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS) Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)
All Cause Mortality
Absorbable Permanent
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/22 (0%) 0/22 (0%)
Serious Adverse Events
Absorbable Permanent
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/22 (0%) 0/22 (0%)
Other (Not Including Serious) Adverse Events
Absorbable Permanent
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 2/22 (9.1%) 4/22 (18.2%)
Reproductive system and breast disorders
Any suture related complication 2/22 (9.1%) 2 4/22 (18.2%) 4

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact

Name/Title Dr. Joseph Kowalski
Organization University of Iowa Hospitals and Clinics
Phone 3193561616
Email joseph-kowalski@uiowa.edu
Responsible Party:
Joseph Kowalski, Female Pelvic Medicine and Reconstructive Surgery, Fellow, University of Iowa
ClinicalTrials.gov Identifier:
NCT02888093
Other Study ID Numbers:
  • 201607769
First Posted:
Sep 2, 2016
Last Update Posted:
Dec 2, 2019
Last Verified:
Nov 1, 2019